Krystal Biotech, Inc.
Krystal Biotech, Inc. (Nasdaq: KRYS) is a commercial-stage biotechnology company that discovers, develops, manufactures and commercializes genetic medicines for diseases with high unmet medical needs. Its proprietary gene therapy platform uses engineered herpes simplex virus-1 vectors to deliver therapeutic genes to… From the company’s description.
In fiscal 2025, Krystal Biotech, Inc. reported revenue of $389.13M, up 33.9% from fiscal 2024, and net income of $204.83M. Its operating margin was 41.5%, and operations generated $200.87M in cash. Over the twelve months to Jun 30, 2026, revenue was $440.48M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Krystal Biotech, Inc. does
In the company’s own words
Krystal Biotech, Inc. (Nasdaq: KRYS) is a commercial-stage biotechnology company that discovers, develops, manufactures and commercializes genetic medicines for diseases with high unmet medical needs. Its proprietary gene therapy platform uses engineered herpes simplex virus-1 vectors to deliver therapeutic genes to target cells. Its first commercial product, VYJUVEK, is a topical gene therapy for dystrophic epidermolysis bullosa, approved in the United States, European Union and Japan. The company sells directly in the United States, major European markets and Japan, and uses specialty distributors elsewhere. Its clinical-stage pipeline includes gene therapies for cystic fibrosis and alpha-1 antitrypsin deficiency lung disease, ocular complications of dystrophic epidermolysis bullosa, neurotrophic keratitis and Hailey-Hailey disease, as well as KB707 for solid tumors. Krystal supports its development and commercial operations with two in-house, commercial-scale manufacturing facilities. Through its wholly owned subsidiary Jeune Aesthetics, it also evaluates its platform for aesthetic conditions.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- PITTSBURGH, PA
- Fiscal year end
- December
- CIK
- 1711279
- SIC
- 2836
Financial performance, year by year
Fiscal 2017–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Krystal Biotech, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Krystal Biotech, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Krystal Biotech, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Krystal Biotech, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Krystal Biotech, Inc.'s last four quarterly filings that the numbers alone won't show?”